α-fetoprotein and ultrasonography screening for hepatocellular carcinoma

Daniele, Bruno; Bencivenga, Alfonso; Megna, Angelo Salomone; Tinessa, Vincenza

doi:10.1053/j.gastro.2004.09.023

Cited by 354 publications

(289 citation statements)

References 24 publications

Supporting

Mentioning

271

Contrasting

Unclassified

Order By: Relevance

“…Xu J et al stated that high levels of AFP (>20 ng/ml) signify a highly malignant tumor and unfavorable prognosis (Xu et al, 2012). In our study fifty four (55.1%) patients had elevated AFP (>20 ng/ml) which is consistent with previous studies (Daniele et al, 2004;Marrero et al, 2004 ). The patients who had AFP level above 20 ng/ml had significantly worse prognosis compare to the patients who had normal level.…”

Section: Discussionsupporting

confidence: 90%

Clinicopathological Characteristics of Hepatocellular Carcinoma in Turkey

Doğan¹,

Yalçın²,

Koca³

et al. 2012

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

Section: Discussionsupporting

confidence: 90%

Clinicopathological Characteristics of Hepatocellular Carcinoma in Turkey

Doğan¹,

Yalçın²,

Koca³

et al. 2012

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

“…Predictably, the use of higher cut-off levels results in increased specificity, but at significant cost to the test's sensitivity. 252 Because AFP assay apparently has relatively poor sensitivity at any cut-off level, it is increasingly argued that it is an inadequate screening test when used on its own. 253 One editorial goes as far as to announce its "Obituary".…”

Section: Serum Afp Testingmentioning

confidence: 99%

Surveillance of cirrhosis for hepatocellular carcinoma: systematic review and economic analysis

Coon¹,

Rogers²,

Hewson³

et al. 2007

Health Technol Assess

151

108

View full text Add to dashboard Cite

Non-UK purchasers will have to pay a small fee for post and packing. For European countries the cost is £2 per monograph and for the rest of the world £3 per monograph.You can order HTA monographs from our Despatch Agents:-fax (with credit card or official purchase order) -post (with credit card or official purchase order or cheque) -phone during office hours (credit card only).Additionally the HTA website allows you either to pay securely by credit card or to print out your order and then post or fax it. NHS libraries can subscribe free of charge. Public libraries can subscribe at a very reduced cost of £100 for each volume (normally comprising 30-40 titles). The commercial subscription rate is £300 per volume. Please see our website for details. Subscriptions can only be purchased for the current or forthcoming volume. Contact details are as follows: Payment methods Paying by chequeIf you pay by cheque, the cheque must be in pounds sterling, made payable to Direct Mail Works Ltd and drawn on a bank with a UK address. Paying by credit cardThe following cards are accepted by phone, fax, post or via the website ordering pages: Delta, Eurocard, Mastercard, Solo, Switch and Visa. We advise against sending credit card details in a plain email. Paying by official purchase orderYou can post or fax these, but they must be from public bodies (i.e. NHS or universities) within the UK. We cannot at present accept purchase orders from commercial companies or from outside the UK. How do I get a copy of HTA on CD?Please use the form on the HTA website (www.hta.ac.uk/htacd.htm). Or contact Direct Mail Works (see contact details above) by email, post, fax or phone. HTA on CD is currently free of charge worldwide.The website also provides information about the HTA Programme and lists the membership of the various committees. Declared competing interests of authors: K Stein received an unrestricted grant from Schering Plough (UK) to carry out work on the cost-effectiveness of combination therapy for hepatitis C in 2000. KS is also a member of the editorial board for Health Technology Assessment, but he was not involved in the editorial process for this report. M Cramp sits on hepatitis C advisory boards for Schering Plough, Gilead and Roche. He has received unrestricted educational grants from Roche and Schering Plough to support research and service development. He has been awarded an NHS R&D grant looking at injecting drug users who do not have hepatitis C virus infection. J Thompson Coon received a grant from the Hepatitis C Trust to conduct a systematic review of complementary and alternative therapies for the treatment of chronic hepatitis C. HTA Published September 2007This report should be referenced as follows: NIHR Health Technology Assessment ProgrammeT he Health Technology Assessment (HTA) programme, now part of the National Institute for Health Research (NIHR), was set up in 1993. It produces high-quality research information on the costs, effectiveness and broader impact of health technologies for those who use, man...

show abstract

“…However, the sensitivity of AFP has been reported to be about 60% in HCC [35]. The elevation of AFP is also associated with benign hepatic diseases such as acute and chronic viral hepatitis as well as toxic liver injury, suggesting that AFP specificity in HCC diagnosis is still not reliable.…”

Section: Alpha Fetoprotein and Hcc Diagnosismentioning

confidence: 99%

Mini-array of multiple tumor-associated antigens to enhance autoantibody detection for immunodiagnosis of hepatocellular carcinoma

Zhang¹

2007

Autoimmunity Reviews

View full text Add to dashboard Cite

Liver cancer, especially hepatocellular carcinoma (HCC), is particularly prevalent in Africa and Asia. HCC affects the Hispanic population of the United States at a rate double that of the white population. The majority of people with HCC will die within 1 year of its detection. This high case-fatality rate can in part be attributed to lack of diagnostic methods that allow early detection. How to establish a methodology to identify the high-risk individuals for HCC remains to be investigated. The multifactorial and multi-step nature in the molecular pathogenesis of human cancers must be taken into account in both the design and interpretation of studies to identify markers which will be useful for early detection of cancer. Our recent studies demonstrated that a mini-array of multiple tumorassociated antigens (TAAs) might enhance autoantibody detection for diagnosis of HCC, especially for the alpha fetoprotein (AFP)-negative cases. It also suggested that different types of cancer might require different panels of TAAs to achieve the sensitivity and specificity required to make immunodiagnosis a feasible adjunct to tumor diagnosis.

show abstract

α-fetoprotein and ultrasonography screening for hepatocellular carcinoma

Cited by 354 publications

References 24 publications

Clinicopathological Characteristics of Hepatocellular Carcinoma in Turkey

Clinicopathological Characteristics of Hepatocellular Carcinoma in Turkey

Surveillance of cirrhosis for hepatocellular carcinoma: systematic review and economic analysis

Mini-array of multiple tumor-associated antigens to enhance autoantibody detection for immunodiagnosis of hepatocellular carcinoma

Contact Info

Product

Resources

About